Today: 27 April 2026

Microsoft (MSFT) Stock After Hours: AI Deals, Norway Fund Showdown and Copilot Launch Shape December 1 Outlook

Microsoft (MSFT) Stock After Hours: AI Deals, Norway Fund Showdown and Copilot Launch Shape December 1 Outlook

Microsoft shares closed at $487.38 on Monday, down 0.9%, as investors digested a major OpenAI partnership restructuring and governance tensions ahead of a shareholder meeting. Volume lagged recent averages, with after-hours trading little changed. The S&P 500 and Nasdaq also slipped, adding pressure. Microsoft’s stake in OpenAI now stands at about 27%, valued near $135 billion.
1 December 2025
··
Tesla Stock After Hours: Burry’s Short, Europe Slump and FSD Trial Shape TSLA Outlook on December 1, 2025

Tesla Stock After Hours: Burry’s Short, Europe Slump and FSD Trial Shape TSLA Outlook on December 1, 2025

Tesla closed Monday near $430, little changed after volatile trading and above-average volume. Michael Burry renewed his bearish stance, calling the stock “ridiculously overvalued” and highlighting shareholder dilution. November sales fell sharply in key European markets. Wall Street forecasts remained mixed and cautious.
1 December 2025
···
Oracle Stock After the Bell: ORCL Holds the Line Around $201 as Wall Street Splits on Its AI Supercycle – Dec. 1, 2025

Oracle Stock After the Bell: ORCL Holds the Line Around $201 as Wall Street Splits on Its AI Supercycle – Dec. 1, 2025

Oracle shares closed just above $200 on December 1, down 40% from September’s record high near $328. The stock slipped less than half a percent Monday after trading between $196.7 and $203.5 on average volume. The sharp decline follows concerns over AI infrastructure spending and Oracle’s rising debt since its strong fiscal Q1 report in September.
1 December 2025
···
Nvidia Stock After the Bell: NVDA Near $180 as $2 Billion Synopsys Stake, HPE Deal and AI Bubble Fears Collide – December 1, 2025

Nvidia Stock After the Bell: NVDA Near $180 as $2 Billion Synopsys Stake, HPE Deal and AI Bubble Fears Collide – December 1, 2025

Nvidia shares closed at $179.98 Monday, up 1.7%, defying declines in major U.S. indexes. The gain followed news of a $2 billion equity stake in Synopsys and expanded AI partnerships. After-hours trading saw Nvidia edge to $180.14. Volume reached about 145 million shares, near its daily average.
1 December 2025
·····
Stock Market Today: Dow Drops 296 Points as Bitcoin Slumps and Fed Jitters Hit Wall Street

Stock Market Today: Dow Drops 296 Points as Bitcoin Slumps and Fed Jitters Hit Wall Street

The Dow fell 296 points to 47,420.77 Monday as the S&P 500 lost 0.34% and the Nasdaq dropped 0.29%. The ISM Manufacturing PMI slid to 48.2, marking a ninth month of contraction. Bitcoin tumbled 7%, dragging crypto stocks lower. Futures markets still price in a December Fed rate cut despite rising dissent within the Fed.
1 December 2025
··········
Apple Stock After the Bell: AAPL Nears $283 as Wall Street Debates Valuation, AI Strategy and the iPhone 17 Boom

Apple Stock After the Bell: AAPL Nears $283 as Wall Street Debates Valuation, AI Strategy and the iPhone 17 Boom

Apple closed Monday near $283, up 1.5%, holding gains after hours and pushing its market cap back above $4 trillion. The stock sits near 52-week highs after a record quarter, with $102.5 billion in revenue and double-digit iPhone growth guidance for the holidays. Technicals show overbought conditions following a 40% six-month rally. New research triggered mixed analyst reactions late Monday.
1 December 2025
··
Silver Price Hits Record Above $58 as 2025 Rally Goes Parabolic – What Comes Next in 2026–2027?

Silver Price Hits Record Above $58 as 2025 Rally Goes Parabolic – What Comes Next in 2026–2027?

Silver surged to record highs above $58 per ounce on December 1, 2025, more than doubling year-to-date. Spot prices touched $58.83 and futures briefly topped $59, driven by supply deficits, strong industrial demand, and a weaker dollar. The rally has outpaced gold, with analysts divided over whether prices can hold above $60. Trading disruptions and shrinking inventories have added to volatility.
1 December 2025
·
Google Stock After Hours: Alphabet (GOOGL) Cools Off, But AI‑Powered Rally Still Dominates the Story

Google Stock After Hours: Alphabet (GOOGL) Cools Off, But AI‑Powered Rally Still Dominates the Story

Alphabet’s Class A shares closed just below $315 on Monday, down about 1% after a run of record highs, before edging up to $315.17 in after-hours trading. The dip followed a surge of headlines on Gemini 3 and new AI chips. Shares remain up roughly 70% year-to-date and nearly 90% over 12 months. Class C shares ended near $316.60, also down about 1%.
1 December 2025
···
Beyond Meat Hit With $38.9M Vegadelphia Verdict as BYND Stock Lures Bullish Options Traders

Beyond Meat Hit With $38.9M Vegadelphia Verdict as BYND Stock Lures Bullish Options Traders

Beyond Meat faces a $38.9 million trademark verdict after a federal jury found it infringed Vegadelphia Foods’ slogan. The company, now trading near $1 per share, is also under new securities-fraud investigations and reported deepening losses and impairments. Beyond Meat says it will appeal the verdict. Cash holdings stood at $131 million against $1.2 billion in debt as of late September.
1 December 2025
Nike (NKE) Stock on December 1, 2025: Ex‑Dividend Drop, Wall Street Targets, and 2026 Outlook

Nike (NKE) Stock on December 1, 2025: Ex‑Dividend Drop, Wall Street Targets, and 2026 Outlook

Nike shares traded around $65.70 on December 1, 2025, up 1–2% intraday despite going ex-dividend for a new $0.41 quarterly payout. The stock is down about 17% over the past year and roughly 50% over five years. Analysts’ average 12-month price target sits in the low-to-mid $80s, implying 25–30% upside from current levels. Nike’s dividend yield now stands near 2.5%.
1 December 2025
···
Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Abbott Laboratories has agreed to acquire Exact Sciences for $105 per share in cash, valuing the deal at up to $23 billion including debt. Exact Sciences stock traded at $101.27 mid-day December 1, near its all-time high after a 56% surge in November. The transaction is expected to close in Q2 2026, pending approvals. The offer represents a 22% premium to Exact’s pre-deal price.
1 December 2025
··
Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook

Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook

Q32 Bio shares jumped as much as 170% intraday on December 1 after announcing the sale of its Phase 2 drug ADX-097 to Akebia Therapeutics for $12 million upfront and up to $592 million in milestones. Trading volume soared into the hundreds of millions. The company will now focus on its lead autoimmune drug, bempikibart, for alopecia areata.
1 December 2025
···
Ford Motor Stock Today: Can High Dividends Offset EV Turbulence and Supply Shocks? (NYSE: F / FORD MTR CO DEL)

Ford Motor Stock Today: Can High Dividends Offset EV Turbulence and Supply Shocks? (NYSE: F / FORD MTR CO DEL)

Ford Motor shares traded near $13.20 on December 1, 2025, after a 42% year-to-date rally. Q3 revenue hit a record $50.5 billion, led by Ford Pro, but the company trimmed its full-year outlook following a supplier fire and a major Bronco recall. Analysts rate the stock “Hold” with targets below the current price. Ford is reportedly reconsidering its EV strategy, including possible changes to the F-150 Lightning lineup.
1 December 2025
··
Coupang (CPNG) Stock Tumbles After Record Data Breach – December 2025 Outlook for Investors

Coupang (CPNG) Stock Tumbles After Record Data Breach – December 2025 Outlook for Investors

Coupang shares fell about 4–5% to $26.90 in New York on December 1 after the company disclosed a data breach affecting 33.7 million customer accounts, nearly its entire South Korean user base. The breach, which began in June and went undetected for months, exposed names, contact details, and order histories. Police are investigating possible involvement by a former Chinese employee.
1 December 2025
·
K&W Cafeterias Closes All Locations Effective Immediately After 88 Years: What Happened and What’s Next

K&W Cafeterias Closes All Locations Effective Immediately After 88 Years: What Happened and What’s Next

K&W Cafeterias closed all nine of its remaining locations in North Carolina and Virginia without warning on December 1, 2025, ending 88 years in business. The company gave no reason for the immediate shutdown. Local news outlets confirmed the closures after K&W posted a farewell message online. The chain had previously filed for bankruptcy in 2020 and was sold in 2022.
1 December 2025
1 … 1,400 1,401 1,402 1,403 1,404 … 1,875

Stock Market Today

  • SQM Valuation Under Scrutiny Amid New Lithium Oversupply Concerns
    April 27, 2026, 5:29 PM EDT. Sociedad Química y Minera de Chile (SQM) faces fresh lithium market oversupply concerns raised by Rothschild & Co Redburn research. Despite recent share price gains-up 7.36% in 30 days and 27.33% year-to-date-SQM trades at $88.79 against a perceived fair value of $75.33, implying a 17.9% overvaluation. Expansion plans in Australia and Chile, including projects like Salar Futuro, bolster long-term growth potential, but lithium price volatility and Chilean regulatory risks cloud the outlook. Conflicting discounted cash flow (DCF) models add uncertainty, with one suggesting an intrinsic value of $113.84, highlighting divergent investor perspectives on SQM's earnings and growth prospects in a shifting lithium market.

Latest article

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

27 April 2026
Oruka Therapeutics reported its experimental psoriasis drug ORKA-001 achieved complete skin clearance in 63.5% of patients at 16 weeks. Shares jumped 10.5% to $76.39 before the company launched a $500 million public offering. No serious adverse events were reported in the trial. ORKA-001 is being developed as a long-acting injectable, with annual dosing possible.
Why Rambus Stock Fell Even as AI Memory Sales Jumped in Q1

Why Rambus Stock Fell Even as AI Memory Sales Jumped in Q1

27 April 2026
Rambus shares fell 10.8% to $141.31 Monday after reporting first-quarter revenue of $180.2 million and net income of $59.9 million. Product revenue rose 15% to $88 million, driven by AI data-center demand. The company forecast higher second-quarter product revenue but said results depend on customer deals. Rambus recently launched a new server memory module aimed at AI systems.
Go toTop